02 March 2017
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
- In vivo research demonstrates potential of novel, proprietary, CARMA product candidate for use in developing immunotherapies for the treatment of solid tumours
Maryland, USA – 2 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present results of pre-clinical in vivoresearch demonstrating the potential of its novel, proprietary, CARMA platform for use in developing immunotherapies for the treatment of solid tumours at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC on 4 April 2017.
Using MaxCyte’s unique, rapid-manufacture CARMA platform in immuno-oncology, MaxCyte and its collaborators at the Johns Hopkins Kimmel Cancer Center demonstrated that preclinical in vivo testing of CARMA-hMeso (i.e., mesothelin-specific mRNA CAR-transfected peripheral blood lymphocytes) containing mesothelin-expressing tumour cells resulted in killing of tumour cells and in increased overall survival; with multiple repeat weekly administration of CARMA-hMeso permitting prolonged control over tumour growth and increased overall survival compared to a single administration.
“These data represent a major pre-clinical milestone for MaxCyte’s CARMA programme as the results demonstrate the ability of a CARMA immunotherapy to effectively inhibit tumour growth and prolong survival in an animal model of disease. The data provide a strong scientific foundation for translational development of our rapid-manufacture CARMA platform to quickly develop tumour-targeted immunotherapies using peripheral blood lymphocytes. We can control ‘on-target, off-tumour’ toxicities, while reducing manufacturing cost and complexity for therapies targeting both solid cancers and hematological malignancies, beyond B-cell tumours.”
Doug DoerflerPresident & Chief Executive Officer
Data will be shared via a poster (Permanent Abstract Number: 3748) at the AACR Annual Meeting 2017 as follows:
Session: “Innate Effectors in Immunity to Cancer”
Date: Tuesday, 4 April 2017
Time: 8:00 a.m. - 12:00 p.m. ET
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
MaxCyte (LSE: MXCT), is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte’s team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is CE-marked and FDA-accredited, providing MaxCyte’s customers and partners with an established regulatory path to commercialize cell-based medicines.
For more information, visit http://www.maxcyte.com/
For further information, please contact:
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
+1 301 944 1660
Nominated Adviser and Broker
Freddy Crossley (Corporate Finance)
Tom Salvesen (Corporate Broking)
+44 (0) 20 7886 2500